Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease

Ahmed A. Moustafa, Mohammad M. Herzallah, Mark Gluck

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background/Aims: Levodopa and dopamine agonists have different effects on the motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Methods: Using a computational model of basal ganglia (BG) and prefrontal cortex (PFC) dopamine, we provide a theoretical synthesis of the dissociable effects of these dopaminergic medications on brain and cognition. Our model incorporates the findings that levodopa is converted by dopamine cells into dopamine, and thus activates prefrontal and striatal D1 and D2 dopamine receptors, whereas antiparkinsonian dopamine agonists directly stimulate D 2 receptors in the BG and PFC (although some have weak affinity to D1 receptors). Results: In agreement with prior neuropsychological studies, our model explains how levodopa enhances, but dopamine agonists impair or have no effect on, stimulus-response learning and working memory. Conclusion: Our model explains how levodopa and dopamine agonists have differential effects on motor and cognitive processes in PD.

Original languageEnglish (US)
Pages (from-to)102-111
Number of pages10
JournalNeurodegenerative Diseases
Volume11
Issue number2
DOIs
StatePublished - Nov 1 2012

Fingerprint

Dopamine Agonists
Levodopa
Parkinson Disease
Learning
Dopamine
Basal Ganglia
Prefrontal Cortex
Antiparkinson Agents
Corpus Striatum
Dopamine D1 Receptors
Dopamine D2 Receptors
Short-Term Memory
Cognition
Psychiatry
Brain

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Keywords

  • Basal ganglia
  • Dopamine agonists
  • Levodopa
  • Parkinson's disease
  • Prefrontal cortex
  • Reinforcement
  • Stimulus-response learning
  • Working memory

Cite this

@article{6c2751fa6d5b4377b8e3ca9296910f14,
title = "Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease",
abstract = "Background/Aims: Levodopa and dopamine agonists have different effects on the motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Methods: Using a computational model of basal ganglia (BG) and prefrontal cortex (PFC) dopamine, we provide a theoretical synthesis of the dissociable effects of these dopaminergic medications on brain and cognition. Our model incorporates the findings that levodopa is converted by dopamine cells into dopamine, and thus activates prefrontal and striatal D1 and D2 dopamine receptors, whereas antiparkinsonian dopamine agonists directly stimulate D 2 receptors in the BG and PFC (although some have weak affinity to D1 receptors). Results: In agreement with prior neuropsychological studies, our model explains how levodopa enhances, but dopamine agonists impair or have no effect on, stimulus-response learning and working memory. Conclusion: Our model explains how levodopa and dopamine agonists have differential effects on motor and cognitive processes in PD.",
keywords = "Basal ganglia, Dopamine agonists, Levodopa, Parkinson's disease, Prefrontal cortex, Reinforcement, Stimulus-response learning, Working memory",
author = "Moustafa, {Ahmed A.} and Herzallah, {Mohammad M.} and Mark Gluck",
year = "2012",
month = "11",
day = "1",
doi = "10.1159/000341999",
language = "English (US)",
volume = "11",
pages = "102--111",
journal = "Neurodegenerative Diseases",
issn = "1660-2854",
publisher = "S. Karger AG",
number = "2",

}

Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease. / Moustafa, Ahmed A.; Herzallah, Mohammad M.; Gluck, Mark.

In: Neurodegenerative Diseases, Vol. 11, No. 2, 01.11.2012, p. 102-111.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease

AU - Moustafa, Ahmed A.

AU - Herzallah, Mohammad M.

AU - Gluck, Mark

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background/Aims: Levodopa and dopamine agonists have different effects on the motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Methods: Using a computational model of basal ganglia (BG) and prefrontal cortex (PFC) dopamine, we provide a theoretical synthesis of the dissociable effects of these dopaminergic medications on brain and cognition. Our model incorporates the findings that levodopa is converted by dopamine cells into dopamine, and thus activates prefrontal and striatal D1 and D2 dopamine receptors, whereas antiparkinsonian dopamine agonists directly stimulate D 2 receptors in the BG and PFC (although some have weak affinity to D1 receptors). Results: In agreement with prior neuropsychological studies, our model explains how levodopa enhances, but dopamine agonists impair or have no effect on, stimulus-response learning and working memory. Conclusion: Our model explains how levodopa and dopamine agonists have differential effects on motor and cognitive processes in PD.

AB - Background/Aims: Levodopa and dopamine agonists have different effects on the motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Methods: Using a computational model of basal ganglia (BG) and prefrontal cortex (PFC) dopamine, we provide a theoretical synthesis of the dissociable effects of these dopaminergic medications on brain and cognition. Our model incorporates the findings that levodopa is converted by dopamine cells into dopamine, and thus activates prefrontal and striatal D1 and D2 dopamine receptors, whereas antiparkinsonian dopamine agonists directly stimulate D 2 receptors in the BG and PFC (although some have weak affinity to D1 receptors). Results: In agreement with prior neuropsychological studies, our model explains how levodopa enhances, but dopamine agonists impair or have no effect on, stimulus-response learning and working memory. Conclusion: Our model explains how levodopa and dopamine agonists have differential effects on motor and cognitive processes in PD.

KW - Basal ganglia

KW - Dopamine agonists

KW - Levodopa

KW - Parkinson's disease

KW - Prefrontal cortex

KW - Reinforcement

KW - Stimulus-response learning

KW - Working memory

UR - http://www.scopus.com/inward/record.url?scp=84868238670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868238670&partnerID=8YFLogxK

U2 - 10.1159/000341999

DO - 10.1159/000341999

M3 - Article

VL - 11

SP - 102

EP - 111

JO - Neurodegenerative Diseases

JF - Neurodegenerative Diseases

SN - 1660-2854

IS - 2

ER -